Patient-reported Outcomes After Prostate Stereotactic Body Radiotherapy at 5 yr: Results from the PACE-B Trial
Authors:
- Sian CooperSCSian Cooper
- Jaymini PatelJPJaymini Patel
- Caroline MooreCMCaroline Moore
- Peter OstlerPOPeter Ostler
- Hans van der VoetHVHans van der Voet
- Andrew LoblawALAndrew Loblaw
- William ChuWCWilliam Chu
- Daniel FordDFDaniel Ford
- Shaun TolanSTShaun Tolan
- Suneil JainSJSuneil Jain
- Philip CamilleriPCPhilip Camilleri
- Kiran KancherlaKKKiran Kancherla
Open Access
- 20 July 2026
- journal article
- Published by Elsevier in European Urology
- Vol. 90 (4) , 321-327
Abstract
No abstract availableFunding Information
- Accuray
This publication has 8 references indexed in Scilit:
- Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate CancerNew England Journal of Medicine, 2024
- Radical Prostatectomy Versus Stereotactic Radiotherapy for Clinically Localised Prostate Cancer: Results of the PACE-A Randomised TrialEuropean Urology, 2024
- Urinary and Sexual Impact of Robotic Radical Prostatectomy: Reporting of Patient-reported Outcome Measures in the First Year after Radical Prostatectomy in a Contemporary Multicentre Cohort in the United KingdomEuropean Urology Open Science, 2024
- Major Complications and Adverse Events Related to Use of SpaceOAR Hydrogel for Prostate Cancer RadiotherapyUrology, 2024
- Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate CancerNew England Journal of Medicine, 2023
- Patient-Reported Outcomes 12 Years after Localized Prostate Cancer TreatmentNEJM Evidence, 2023
- Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate CancerJAMA, 2020
- Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trialThe Lancet Oncology, 2019